The SUNLIGHT trial for metastatic colorectal cancer was a
The SUNLIGHT trial for metastatic colorectal cancer was a pivotal Phase III study jointly sponsored and funded by the pharmaceutical companies Servier and Taiho Oncology.
The global study was led by Dr. Josep Tabernero, head of medical oncology at the Vall d’Hebron University Hospital in Barcelona, Spain.
The trial's steering committee also included a global panel of gastrointestinal cancer experts, such as:
Dr. Gerald W. Prager (Medical University of Vienna, Austria)
Dr. Julien Taieb (Georges Pompidou European Hospital, Paris, France)
Dr. Marwan Fakih (City of Hope Comprehensive Cancer Center, Duarte, CA)
Dr. Eric Van Cutsem (University Hospitals Gasthuisberg, Leuven, Belgium)
Dr. J said of the 246 SUNLIGHT patients, 2 weeks ctDNA @ 3%, was the real world data & none had a full responsive rate
& this trial will be Leronlimabs, "comparable" trial, the FDA will use.
COH is loving on Leronlimab !!
3
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Perigon is rearranging the engine room before the next growth spurt gets noisy. The firm has named Christopher Broderick Director of Investments and Research, added two trading associates, and put another brick behind the broader operating structure Rafia Hasan has been assembling since taking on the chief operating officer role in August. That may sound like ordinary...
Continue Reading
Small Classroom Moments Finally Get Their Due A child’s hesitant question can disappear in the noise of a busy classroom, which is precisely why Teachstone’s latest recognition deserves more than the usual polite golf clap. The Charlottesville-based Certified B Corporation received a Bronze Anthem Award for its “From Measurement to Momentum” initiative, in the...
Continue Reading
A thermostat war in the bedroom is a lousy reason to buy the wrong mattress. Yet that is the mundane, very real problem Sleep Number is leaning into after Expert Consumers named it a leading 2026 choice for couples seeking personalized sleep comfort. The company’s argument is straightforward: two people sharing a bed should not have to share one firmness setting, or...
Continue Reading
A blurry Montana kitchen, not a glossy product render, is doing the heavy lifting for CASEKOO this Thanksgiving. That is either a smart bit of brand discipline or a sentimental detour, depending on whether the company can make people feel something without losing sight of why they bought a phone case in the first place. Warmth Takes the Place of Hardware CASEKOO's new...
Continue Reading
Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...
Continue Reading
A language gap rarely makes the loudest noise in an earnings call, yet it can quietly wreck a sales effort, a hiring plan, or a customer relationship. ACTFL's updated 2026 employer study puts some hard edges around that problem: U.S. businesses say multilingual capability is not a nice cultural accessory. It is increasingly part of operating the business. Demand Has Moved...
Continue Reading
A toddler surviving on three bites Tuesday is not a verdict on the family table. That plain idea sits at the center of pediatric expert Kathy Shirazi’s guidance on childhood nutrition, and frankly, it deserves more oxygen than another impossible-looking lunchbox photo. In the HelloNation article released November 20, 2026, Shirazi, MD, MPH, FAAP, urges parents to judge...
Continue Reading
A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...
Continue Reading
A glucose sensor is becoming less a gadget than a running conversation between patient, clinician and software. That shift matters because diabetes management is leaving the occasional clinic visit and moving into daily life, where the useful product is not merely a reading but a pattern someone can act on. The sector deserves attention from investors, but it also...
Continue Reading
Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...
Continue Reading
Top 5 Most Recently Viewed Articles
Specialty1 Partners Fuels Growth with Innovative Model Specialty1 Partners (S1P) has emerged as a leader in the specialty dental partnership sector, focusing on aiding Endodontists, Periodontists, and Oral Surgeons in elevating their practices. Their innovative joint venture model is increasingly attracting dental specialists eager to transition from associates to...
Continue Reading
Union Pacific's Ambitious Merger Talks Union Pacific Corp. (NYSE: UNP) is reportedly engaged in preliminary discussions to acquire Norfolk Southern Corp. (NYSE: NSC), marking a prospective mega-merger in the railroad industry. While details are still emerging, the implications of such a merger could significantly reshape the freight transport landscape across the United...
Continue Reading
Overview of Financial Achievements Great Elm Capital Corp. (NASDAQ: GECC) has recently released its financial performance report for the second quarter, demonstrating remarkable growth and a prosperous quarter for the company. This update is essential for investors and stakeholders keen on understanding the company's current financial health and future prospects. Record...
Continue Reading
Scandinavian Tobacco Group A/S launched a significant share buy-back program back in November, worth up to DKK 850 million. The move aimed at adjusting the company's capital structure and meeting obligations tied to its share-based incentive programs. This isn’t just a random act; it’s a strategic ploy in a competitive market that’s meant to bolster their stock...
Continue Reading
Exciting Developments in Telitacicept Phase III Trial Results The Phase III clinical trial results for Telitacicept are sparking significant interest, particularly within the realm of Sjögren's Syndrome. This autoimmune condition can severely affect patients' quality of life due to symptoms like dry mouth and dry eyes, among others. Recently, announcements surrounding...
Continue Reading